CU20070160A7 - Pirrolopirazoles, inhibidores potentes de quinasa - Google Patents

Pirrolopirazoles, inhibidores potentes de quinasa

Info

Publication number
CU20070160A7
CU20070160A7 CU20070160A CU20070160A CU20070160A7 CU 20070160 A7 CU20070160 A7 CU 20070160A7 CU 20070160 A CU20070160 A CU 20070160A CU 20070160 A CU20070160 A CU 20070160A CU 20070160 A7 CU20070160 A7 CU 20070160A7
Authority
CU
Cuba
Prior art keywords
pirrolopirazoles
powerful
inhibitors
quinasa
quinasa inhibitors
Prior art date
Application number
CU20070160A
Other languages
English (en)
Other versions
CU23778B7 (es
Inventor
Anle Yang
Junhu Zhang
Haitao Li
Chuangxing Guo
Liming Dong
Djamal Bouzida
Yufeng Hong
Joseph Timothy Marakovits
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CU20070160A7 publication Critical patent/CU20070160A7/es
Publication of CU23778B7 publication Critical patent/CU23778B7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se proporcionan compuestos de pirrolo-pirazol de fórmula I, composiciones que incluyen estos compuestos y procedimientos de su uso. Los compuestos preferidos de fórmula I tienen actividad como inhibidores de proteína cinasa, incluyendo como inhibidores de PAK4.
CU20070160A 2005-01-10 2007-07-09 Pirrolopirazoles, inhibidores potentes de quinasa CU23778B7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64290005P 2005-01-10 2005-01-10
US73377005P 2005-11-04 2005-11-04

Publications (2)

Publication Number Publication Date
CU20070160A7 true CU20070160A7 (es) 2009-03-16
CU23778B7 CU23778B7 (es) 2012-02-15

Family

ID=36463340

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070160A CU23778B7 (es) 2005-01-10 2007-07-09 Pirrolopirazoles, inhibidores potentes de quinasa

Country Status (29)

Country Link
US (2) US8067591B2 (es)
EP (1) EP1838718B1 (es)
JP (1) JP4250195B2 (es)
KR (1) KR100919343B1 (es)
CN (1) CN101115760B (es)
AP (1) AP2007004061A0 (es)
AT (1) ATE512972T1 (es)
AU (1) AU2005323797B2 (es)
BR (1) BRPI0518509A2 (es)
CA (1) CA2593428C (es)
CU (1) CU23778B7 (es)
CY (1) CY1111752T1 (es)
DK (1) DK1838718T3 (es)
EA (1) EA011815B1 (es)
ES (1) ES2365245T3 (es)
GE (1) GEP20094785B (es)
HR (1) HRP20110485T1 (es)
IL (1) IL184275A0 (es)
MA (1) MA29141B1 (es)
MX (1) MX2007008385A (es)
NO (1) NO20073859L (es)
NZ (1) NZ556273A (es)
PL (1) PL1838718T3 (es)
PT (1) PT1838718E (es)
RS (1) RS51891B (es)
SI (1) SI1838718T1 (es)
TN (1) TNSN07254A1 (es)
WO (1) WO2006072831A1 (es)
ZA (1) ZA200705628B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP0808A (xx) * 2005-12-21 2010-02-10 Pfizer Prod Inc Karbonilamino pirolopirayoli, snažni inhibitori kinaza
JP5161245B2 (ja) 2007-02-07 2013-03-13 ファイザー・インク ＰＫＣ阻害剤としての３−アミノ−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルボアルデヒド誘導体
UA96618C2 (en) * 2007-02-07 2011-11-25 Пфайзер Инк. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
CA2683695C (en) 2007-04-12 2013-06-18 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
EP2145891A1 (en) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
US20120283296A1 (en) * 2009-10-06 2012-11-08 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
EP2640369A1 (en) 2010-11-17 2013-09-25 F.Hoffmann-La Roche Ag Methods of treating tumors
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9055750B2 (en) 2012-02-03 2015-06-16 Basf Se Fungicidal pyrimidine compounds
WO2013113778A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
US9072301B2 (en) 2012-02-03 2015-07-07 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
JP2015512891A (ja) 2012-03-13 2015-04-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
EP2844248A1 (en) * 2012-03-16 2015-03-11 F. Hoffmann-La Roche AG Methods of treating melanoma with pak1 inhibitors
MX2015003535A (es) 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
WO2014060900A1 (en) * 2012-10-15 2014-04-24 Pfizer Ireland Pharmaceuticals Process for the preparation of voriconazole and analogues thereof
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
EP3046915A1 (en) 2013-09-16 2016-07-27 Basf Se Fungicidal pyrimidine compounds
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3309163A4 (en) 2015-06-15 2019-01-09 UBE Industries, Ltd. SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
CN104926735A (zh) * 2015-06-16 2015-09-23 上海合全药物研发有限公司 4-氯-5-氟-2-甲基嘧啶的工业化制备方法
EP3394056B1 (en) 2015-12-22 2021-04-14 Shy Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
CA3041563C (en) 2016-11-22 2023-10-31 Dana-Farber Cancer Institute, Inc. Pyrimidin-2-amine derivatives and pharmaceutical compositions thereof useful as inhibitors of cyclin-dependent kinase 12 (cdk12)
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US20210161943A1 (en) * 2018-04-16 2021-06-03 The Regents Of The University Of California Pak4 inhibitors and methods of use
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
JP7769388B2 (ja) 2019-12-12 2025-11-13 ティン セラピューティクス，インコーポレイテッド 聴覚損失の予防及び治療のための組成物及び方法
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
CN111454278B (zh) * 2020-05-15 2021-03-19 四川大学 Pak1抑制剂及其合成和在制备抗肿瘤药物中的应用
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
EP4273135A4 (en) * 2020-12-31 2024-11-20 Scinnohub Pharmaceutical Co., Ltd PLASMIN INHIBITOR, ITS PREPARATION METHOD AND ITS APPLICATION
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2025078334A1 (en) 2023-10-09 2025-04-17 Institut National de la Santé et de la Recherche Médicale Combination of pak1 inhibitors and clk inhibitors for preventing resistance to chemotherapy in patients suffering from acute myeloid leukemia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423414A (en) * 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) * 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
US3947467A (en) * 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
JPS5163193A (ja) 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US6013500A (en) * 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase
KR100904157B1 (ko) * 2000-08-10 2009-06-23 파마시아 이탈리아 에스.피.에이. 키나제 억제제로서 활성인 비사이클로-피라졸, 이의제조방법 및 이를 포함하는 약제학적 조성물
AU2003244649A1 (en) 2002-07-25 2004-02-23 Pharmacia Italia Spa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
JP4250195B2 (ja) 2009-04-08
IL184275A0 (en) 2007-10-31
TNSN07254A1 (en) 2008-12-31
HRP20110485T1 (hr) 2011-07-31
JP2008526826A (ja) 2008-07-24
ES2365245T3 (es) 2011-09-27
SI1838718T1 (sl) 2011-08-31
KR20070096007A (ko) 2007-10-01
WO2006072831A1 (en) 2006-07-13
CU23778B7 (es) 2012-02-15
US8530652B2 (en) 2013-09-10
CA2593428A1 (en) 2006-07-13
US20120264751A1 (en) 2012-10-18
CY1111752T1 (el) 2015-10-07
GEP20094785B (en) 2009-09-25
ZA200705628B (en) 2008-11-26
EP1838718B1 (en) 2011-06-15
BRPI0518509A2 (pt) 2008-11-25
US8067591B2 (en) 2011-11-29
AU2005323797A1 (en) 2006-07-13
NZ556273A (en) 2010-01-29
RS51891B (sr) 2012-02-29
US20100222342A1 (en) 2010-09-02
MA29141B1 (fr) 2008-01-02
DK1838718T3 (da) 2011-07-25
KR100919343B1 (ko) 2009-09-25
MX2007008385A (es) 2007-08-21
NO20073859L (no) 2007-10-03
EP1838718A1 (en) 2007-10-03
HK1114380A1 (en) 2008-10-31
PL1838718T3 (pl) 2011-10-31
AU2005323797B2 (en) 2009-07-09
CN101115760B (zh) 2010-11-03
CN101115760A (zh) 2008-01-30
CA2593428C (en) 2012-04-17
AP2007004061A0 (en) 2007-08-31
EA200701257A1 (ru) 2007-12-28
PT1838718E (pt) 2011-08-17
EA011815B1 (ru) 2009-06-30
ATE512972T1 (de) 2011-07-15

Similar Documents

Publication Publication Date Title
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
UY30748A1 (es) Compuesto0s novedosos
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
NO20071127L (no) Triazoloftalaziner
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200700189A1 (ru) Производные хиназолина в качестве ингибиторов parp
EA201070278A1 (ru) Ингибиторы гамма-секретазы
CR8986A (es) Isoxazoles sustituidos como fungicidas
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
NO20081636L (no) FAP - inhibitorer
EA200700185A1 (ru) Производные хиназолиндиона в качестве ингибиторов parp
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
UY30801A1 (es) Compuestos calciliticos
EA200901504A1 (ru) Производные пиразолона, как ингибиторы pde4
CR7961A (es) Compuestos de aminoheteroarilo como inhibidores de las proteinquinasas
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
ATE512967T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
ECSP066931A (es) Nuevos imidazoles
CR9238A (es) Pirrolopirazoles, potentes inhibidores de cinasa
ECSP077378A (es) Isoxazoles sustituidos como fungicidas
ATE533769T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)